A Phase IV, Post-marketing, Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice

PerCuro Clinical Research Ltd1 site in 1 country150 target enrollmentMay 2007

ConditionsRheumatoid Arthritis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Rheumatoid Arthritis
Sponsor: PerCuro Clinical Research Ltd
Enrollment: 150
Locations: 1
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study was designed to gather data regarding the efficacy and safety of Rituxan in clinical practice whereby patients may present with concomitant medical conditions, medications as well as varying presentations of rheumatoid arthritis not always captured within the "purer" population seen in an industry sponsored clinical trial.

Registry

clinicaltrials.gov

Start Date

May 2007

End Date

December 2015

Last Updated

15 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

PerCuro Clinical Research Ltd

Eligibility Criteria

Inclusion Criteria

•Subjects with active rheumatoid arthritis as defined by ACR criteria
•\> 18 years of age at time of consent
•Able to start RITUXAN therapy per the approved product monograph within approximately 30 days of confirmed enrollment

Exclusion Criteria

•Known Type 1 hypersensitivity or anaphylactic reactions to murine proteins, Chinese Hamster Ovary cell proteins or to any component of RITXAN as per approved Product monograph
•Presence of any significant and or uncontrolled medical condition, which in the Investigator's opinion, precludes the use of RITUXAN as outlined in the Product Monograph